PMC9801096_01
Haematological response in RopegIFN treated patients, x axis represents the time in months following the initiation of ropegIFN treatment A) Platelet count response to RopegIFN and in case 1 from 5 months, platelet count response to ANA B) WCC response to RopegIFN in case 5.
gr1.jpg
PMC9801096_05_gr1.jpg
fig0001
After 14 months, she remains on ropegIFN 350 mcg every two weeks, with improved counts (Fig. 1) and reduction in spleen size to 20.3 cm.
PMC9801096_02
Haematological response in RopegIFN treated patients, x axis represents the time in months following the initiation of ropegIFN treatment A) Platelet count response to RopegIFN and in case 1 from 5 months, platelet count response to ANA B) WCC response to RopegIFN in case 5.
gr1.jpg
PMC9801096_05_gr1.jpg
fig0001
After 14 months, she remains on ropegIFN 350 mcg every two weeks, with improved counts (Fig. 1) and reduction in spleen size to 20.3 cm.
PMC9801096_03
Haematological response in RopegIFN treated patients, x axis represents the time in months following the initiation of ropegIFN treatment A) Platelet count response to RopegIFN and in case 1 from 5 months, platelet count response to ANA B) WCC response to RopegIFN in case 5.
gr1.jpg
PMC9801096_05_gr1.jpg
fig0001
After 14 months, she remains on ropegIFN 350 mcg every two weeks, with improved counts (Fig. 1) and reduction in spleen size to 20.3 cm.
PMC9801096_04
Haematological response in RopegIFN treated patients, x axis represents the time in months following the initiation of ropegIFN treatment A) Platelet count response to RopegIFN and in case 1 from 5 months, platelet count response to ANA B) WCC response to RopegIFN in case 5.
gr1.jpg
PMC9801096_05_gr1.jpg
fig0001
After 14 months, she remains on ropegIFN 350 mcg every two weeks, with improved counts (Fig. 1) and reduction in spleen size to 20.3 cm.
PMC9801096_05
Haematological response in RopegIFN treated patients, x axis represents the time in months following the initiation of ropegIFN treatment A) Platelet count response to RopegIFN and in case 1 from 5 months, platelet count response to ANA B) WCC response to RopegIFN in case 5.
gr1.jpg
PMC9801096_05_gr1.jpg
fig0001
After 14 months, she remains on ropegIFN 350 mcg every two weeks, with improved counts (Fig. 1) and reduction in spleen size to 20.3 cm.